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Lifetime Risk of Lower-Extremity Peripheral Artery Disease Defined by
Ankle-Brachial Index in the United States
Kunihiro Matsushita, MD, PhD; Yingying Sang, MS; Hongyan Ning, MD, MS; Shoshana H. Ballew, PhD; Eric K. Chow, MS;
Morgan E. Grams, MD, PhD; Elizabeth Selvin, PhD; Matthew Allison, MD, MPH; Michael Criqui, MD, MPH; Josef Coresh, MD, PhD;
Donald M. Lloyd-Jones, MD, ScM; John T. Wilkins, MD, MS
Background-—There are no available lifetime risk estimates of lower-extremity peripheral artery disease (PAD).
Methods and Results-—Using data from 6 US community-based cohorts and the vital statistics, we estimated the prevalence and
incidence of PAD, defined as an ankle-brachial index < 0.90, at each year of age from birth to 80 years for white, black, and
Hispanic men and women. Then, we used Markov Monte Carlo simulations in a simulated cohort of 100 000 individuals to estimate
lifetime risk of PAD. On the basis of odds ratios of PAD for traditional atherosclerotic risk factors (eg, diabetes mellitus and
smoking), we developed a calculator providing residual lifetime risk of PAD. In an 80-year horizon, lifetime risks of PAD were 30.0%
in black men and 27.6% in black women, but 19% in white men and women and 22% in Hispanic men and women. From another
perspective, 9% of blacks were estimated to develop PAD by 60 years of age, while the same proportion was seen at 70 years for
whites and Hispanics. The residual lifetime risk within the same race/ethnicity varied by 3.5- to 5-fold according to risk factors (eg,
residual lifetime risk in 45-year-old black men was 19.9% when current smoking, diabetes mellitus, and history of cardiovascular
disease were absent versus 70.4% when all were present).
Conclusions-—In the United States, 30% of blacks are estimated to develop PAD during their lifetime, whereas the corresponding
estimate is 20% for whites and Hispanics. The residual lifetime risk within the same race/ethnicity substantially varies according
to traditional risk factors. ( J Am Heart Assoc. 2019;8:e012177. DOI: 10.1161/JAHA.119.012177.)
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L ifetime risk is useful for communicating long-term riskand estimating the future burden of disease in popula-
tions.1–5 Lifetime risk estimation of coronary heart disease
and stroke is recommended in the American Heart Associa-
tion and the American College of Cardiology guidelines for
guiding preventive therapies.6,7 However, to our knowledge,
there are no available estimates of lifetime risk of lower-
extremity peripheral artery disease (PAD), despite its impact
on prognosis,8 leg amputation,9 and physical function.10 Here,
using data from 6 US community-based cohorts with over
35 000 unique participants, we estimated lifetime risk of PAD
by sex and among 3 racial/ethnic groups (whites, blacks, and
Hispanics). Subsequently, we extended the lifetime risk
estimations by age and other traditional atherosclerotic risk
factors, which would complement lifetime risk prediction of
coronary disease and stroke in the American Heart Associ-
ation/American College of Cardiology guidelines6,7 and
facilitate personalized and comprehensive cardiovascular risk
discussion between healthcare providers and patients.6,11
Methods
This study was approved by the institutional review board for
use of deidentified data at the Johns Hopkins Bloomberg
School of Public Health (Baltimore, MD), and the need for
informed consent was waived. Each participating cohort has
its own policy for data sharing, but some of their data are
publicly available (the National Health and Nutrition Examina-
tion Survey [NHANES] through the Centers for Disease
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Control and Prevention’s website12 and other cohorts through
BioLINCC13).
Lifetime Risk Estimation
There are 2 main approaches to estimate lifetime risk in the
literature: (1) estimating long-term cumulative incidence from
a survival analysis of individuals14–16 and (2) estimating
lifetime risk using Monte Carlo simulations with state
transition probabilities based on a Markov chain model.1,2
The former approach may sound more intuitive than the latter,
but because there are few cohort studies with lifelong follow-
up, the former approach often needs to stack cumulative
incidences from different risk sets with different age
categories. For example, to obtain lifetime risk from the age
of 40 in a cohort with an age range of 40 to 80 years and
follow-up of 20 years, cumulative incidence before and after
the age of 60 years should rely on younger and older study
populations, respectively, which potentially induces some
biases (eg, birth cohort effects). Also, the former approach is
likely to be particularly suboptimal for clinical conditions
without evident signs or symptoms, as incidences may not be
appropriately captured in any cohort studies. This issue is
especially relevant to PAD because the vast majority of
disease is asymptomatic or accompanied by atypical leg
symptoms.17 Also, very few cohort studies have regularly
repeated measurement of ankle-brachial index (ABI) in a
relatively short elapsed time to capture asymptomatic cases
to minimize the number of losses to follow-up or deaths
between repeated ABI measurements. Thus, we estimated the
lifetime risk of PAD using the Monte Carlo simulations
approach.2
A Markov chain model was constructed to simulate
progression of an initially PAD free individual of a given
baseline age, sex, and race/ethnicity through the mutually
exclusive states of no PAD, PAD, and death, with PAD and
death treated as “absorbing states” (once entered unable to
leave) (Data S1). State transition probabilities of interest were
(1) the probability of developing PAD (IPAD) and (2) the
probability of dying prior to the development of PAD (QnoPAD).
Details for the calculations of each state transition probability
are provided subsequently in the section “State Transition
Probabilities and Data Sources” below as well as in Data S1.
Using these state transition probabilities, Monte Carlo
simulations were performed 100 000 times from the age of
0 through 80 years with a cycle length of 1 year, which is
equivalent to a simulated cohort of 100 000 individuals of a
specified baseline age, sex, and race with a lifetime horizon
capped at 80 years. All analyses were performed by Stata 14
(StataCorp LP, College Station, TX).
State Transition Probabilities and Data Sources
QnoPAD (1-year probability of dying among people free of PAD
of a given age, sex, and race) was calculated from age-, sex-,
and race/ethnicity-specific estimates of annual mortality in
the overall population (ie, populations with and without PAD),
the prevalence of PAD, and hazard ratios for mortality
associated with PAD. This approach is based on the fact that
annual overall mortality can be viewed as a weighted average
of the 1-year probability of dying among people with PAD and
that of those without PAD.2 Annual probabilities of death for
the US population by each year of age, sex, and race/ethnicity
(whites, blacks, and Hispanics) were based on the National
Vital Statistics Report.18 The prevalence of PAD according to
ABI <0.9019,20 was based on data from a total of 6 US
community-based cohorts (5 cohorts with ABI data included in
the Cardiovascular Lifetime Risk Pooling Project,21 namely, the
ARIC [Atherosclerosis Risk in Communities] study,22 the CHS
[Cardiovascular Health Study],23 the FHS [Framingham Heart
Study],24 the FOF [Framingham Offspring study], and the
MESA [Multi-Ethnic Study of Atherosclerosis],25 as well as
NHANES 1999–2004).26 Data collection in each study was
conducted according to a standardized protocol as previously
reported,22–25 and details of how ABI was measured in each
cohort are summarized in Data S2. The relative risk of
mortality for PAD versus no PAD was also obtained from
pooled data from these 6 US community-based cohorts.
Clinical Perspective
What Is New?
• In blacks, 30% of men and women were estimated to
develop peripheral artery disease (PAD) during their lifetime,
whereas in whites and Hispanics the corresponding esti-
mate is 20%.
• From another perspective, blacks reached a 10% lifetime
risk for PAD 10 years earlier than whites and Hispanics.
• Current and former smoking, diabetes mellitus, and a
history of other cardiovascular disease were particularly
potent predictors of developing PAD, contributing to 5-fold
gradient of residual lifetime risk and 10-fold gradient of
the probability of prevalent PAD at a given age, sex, and
race/ethnicity.
What Are the Clinical Implications?
• Although major guidelines for PAD did not specify black race
as a risk factor of PAD, our results suggest the importance
for healthcare providers to keep in mind this disproportional
risk of PAD in blacks.
• Risk calculators for the lifetime risk of PAD as well as
prevalent PAD have been developed from this study, which
may contribute to comprehensive cardiovascular risk
assessment and inform targeted PAD screening.
DOI: 10.1161/JAHA.119.012177 Journal of the American Heart Association 2
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IPAD (the probability of developing PAD at a given age) was
estimated from age-, sex-, and race/ethnicity-specific esti-
mates of annual mortality in the overall population, QnoPAD
(detailed above), age-, sex-, and race/ethnicity-specific
prevalence of no PAD (ie, 1- the prevalence of PAD). This
approach is based on the fact that the prevalence of no PAD
at age x+1 is determined by 3 elements, the prevalence of no
PAD at age x (denominator) and 2 types of exits from no PAD,
annual incidence of PAD during age x or mortality among no
PAD during age x (ie, QnoPAD). Data sources for these
parameters were the same as those noted above for QnoPAD.
More details about state transition probabilities are provided
in Data S1.
Estimating the Prevalence of PAD
Logistic regression models with age, sex, and race/ethnicity
as independent variables were used to estimate the preva-
lence of PAD. To improve the precision of age-, sex-, and
race/ethnicity-specific estimates of PAD prevalence, we used
the pooled data of the 6 US cohort studies (indicators of 6
cohorts were included in logistic models).2 Because NHANES
is most representative of US populations among the 6 cohorts
(although data were somewhat sparse in some age and race/
ethnic groups), we combined the odds of PAD in a base case
of 70-year-old white men in NHANES and odds ratios for age,
sex, and race/ethnicity from the pooled data to estimate the
prevalence of PAD for each year of age among sex and race/
ethnicity groups (white men and women, black men and
women, and Hispanic men and women). In this step, we used
sample weights in NHANES. We also incorporated significant
product terms between age, race/ethnicity, and sex.
Estimating Relative Risk of Mortality for PAD
Versus No PAD
The relative risk of mortality for PAD (ABI <0.90) versus no
PAD (ABI ≥0.90) was obtained from pooled data from the 6
US community-based cohorts using stratified Cox propor-
tional hazards models. Cox models were adjusted for sex and
race/ethnicity and incorporated interaction terms between
PAD and age with splines (knots at age 65 years). Again,
indicator variables for 6 cohorts were included in regression
models.
Residual Lifetime Risk by Age and Traditional
Atherosclerotic Risk Factors
Lifetime risk estimates from a given age (ie, residual lifetime
risk) can be viewed as a weighted average of residual lifetime
risk of subgroups determined by combinations of the
presence and absence (or higher and lower values if
continuous factors) of traditional risk factors at that given
age. Using sample weights and actual values of traditional
atherosclerotic risk factors in NHANES, as well as odds ratio
of PAD for traditional atherosclerotic risk factors from the
pooled data of 6 studies, we estimated residual lifetime risk
by combinations of age and traditional atherosclerotic risk
factors. More details can be found in Data S3.
Logistic regression models to estimate odds ratios of PAD
in the pooled data of the 6 US cohort studies included
diabetes mellitus, smoking (both current and former), systolic
blood pressure, high-density lipoprotein cholesterol, total
cholesterol, and a history of coronary heart disease or stroke
as well as age, sex, race/ethnicity, and study indicators.
Results
Study Characteristics
A total of 38 154 participants were included from the 6
cohorts, of whom 2517 participants (6.6%) had PAD based on
an ABI <0.90. Whites and blacks were included in 4 cohorts:
ARIC, CHS, MESA, and NHANES (Table 1). Hispanics were
represented in 2 cohorts, MESA and NHANES. The mean age
ranged from 55 to 80 years across the cohorts. Compared
with cohorts with a lower average age, cohorts with an older
average age tended to have a less favorable risk factor profile
(eg, higher blood pressure and prevalence of diabetes
mellitus). The prevalence of current smokers was highest in
ARIC (26%) and lowest in FHS (6.7%). The prevalence of PAD
varied from 3.8% in MESA to 21% in FHS. Generally consistent
across cohorts, a history of coronary heart disease and stroke
as well as most traditional atherosclerotic risk factors (ie, ever
smokers, low high-density lipoprotein cholesterol, and dia-
betes mellitus) were more prevalent in men than in women
(Table S1).
Estimates of PAD Prevalence and Mortality Risk
Associated With PAD
Pooled results from logistic regression models confirmed age
as a strong predictor of prevalent PAD, with an odds ratio of
1.56 (95% CI, 1.50–1.61) per 5-year increment (Table S2). At
65 years of age, women had slightly higher odds of having ABI
<0.90 than men (odds ratio, 1.24 [95% CI, 1.12–1.38]), and
this sex-difference was slightly but significantly attenuated
with older age (as represented by odds ratio of 0.90 [per 5-
year increment] for the product term of female and age).
Compared with whites, blacks had >2-fold higher odds of
having PAD (eg, 2.16 [95% CI, 1.86–2.52] for black men
versus white men), without any difference by age. Hispanics
had significantly lower odds of PAD than whites, especially in
middle age (eg, 0.76 [95% CI, 0.62–0.93] for men at 65 years
DOI: 10.1161/JAHA.119.012177 Journal of the American Heart Association 3
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of age versus white men), but this difference was attenuated
at older ages (1.16 [95% CI, 1.06–1.27] for the product term
of age and Hispanic ethnicity). Estimates of PAD prevalence
were higher in blacks than the other 2 racial/ethnic groups in
either sex at any age (Figure S1).
Pooled Cox models demonstrated a sex- and race/
ethnicity-adjusted hazard ratio of 2.43 (95% CI, 2.18–2.72
at age of 65 years) for total mortality comparing PAD (ABI
<0.90) versus no PAD (ABI ≥0.90) (Table S3). The strength of
association was slightly attenuated in older age (13% [95% CI,
8–17%] smaller hazard ratio per 5 year older age above
65 years) (Table S3).
Lifetime Risk Estimates by Sex and Race/
Ethnicity
Using estimates of PAD prevalence and relative risk of
mortality for PAD in the prior section as well as national
mortality data, we estimated QnoPAD (1-year probability of
dying among people of a given age, sex, and race/ethnicity
and free of PAD) and IPAD (the probability of developing PAD at
a given age) at each age from birth to 80 years in each sex
and racial/ethnic group (Table S4). On the basis of these
estimates, the lifetime risk estimate was highest in black men,
at 30.0%, followed by 27.6% in black women (Figure). The
lifetime risk estimate was similar in white men and women,
Table 1. Study Characteristics
Study
ARIC (14 274) CHS (5662) FHS (597) FOF (3520) MESA (6772) NHANES (7329)
Total of death, N (%) 4272 (30%) 4608 (81%) 430 (72%) 380 (12%) 1144 (17%) 1516 (21%)
Follow-up time (y), mean (SD) 18.4 (5.2) 13.1 (6.5) 9.1 (3.9) 10.3 (2.1) 12.4 (2.5) 9.0 (2.6)
Age (y), mean (SD) 55 (5.9) 72 (5.5) 80 (3.9) 58 (9.6) 62 (10) 60 (13)
Female sex, N (%) 7757 (54%) 3234 (57%) 376 (63%) 1870 (53%) 3573 (53%) 3581 (48%)
Race/Ethnicity, N (%)
White 10 719 (75%) 4790 (85%) 597 (100%) 3520 (100%) 2614 (39%) 4092 (56%)
Black 3555 (25%) 837 (15%) . . . . . . 1868 (28%) 1361 (19%)
Hispanic . . . 35 (0.62%) . . . . . . 2290 (34%) 1876 (26%)
Smoking status, N (%)
Never 5863 (41%) 2615 (47%) 557 (93%) 2977 (85%) 3403 (50%) 3063 (42%)
Former 4699 (33%) 2369 (42%) . . . . . . 2489 (37%) 3292 (45%)
Current 3712 (26%) 678 (12%) 40 (6.7%) 543 (15%) 880 (13%) 967 (13%)
SBP (mm Hg), mean (SD) 121 (19) 136 (22) 143 (21) 128 (18) 126 (21) 132 (21)
Total cholesterol (mmol/L), mean (SD) 5.6 (1.1) 5.5 (1.0) 5.3 (1.0) 5.3 (1.0) 5.0 (0.9) 5.4 (1.1)
HDL cholesterol (mmol/L), mean (SD) 1.3 (0.4) 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.4 (0.4)
Diabetes mellitus, N (%) 1579 (11%) 837 (15%) 130 (22%) 336 (9.6%) 848 (13%) 1200 (16%)
History of CHD or stroke, N (%) 1796 (13%) 893 (16%) 136 (23%) 221 (6.3%) 5 (0.07%) 914 (13%)
ABI, mean (SD) 1.13 (0.14) 1.06 (0.18) 1.01 (0.21) 1.11 (0.12) 1.11 (0.12) 1.09 (0.16)
PAD (ABI <0.90), N (%) 634 (4.4%) 759 (13%) 124 (21%) 112 (3.2%) 255 (3.8%) 633 (8.6%)
ABI indicates ankle-brachial index; ARIC, Atherosclerosis Risk in Communities study; CHD, coronary heart disease; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; FOF,
Framingham Offspring study; HDL, high-density lipoprotein; MESA, Multi-Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Examination Survey; PAD, peripheral
artery disease; SBP, systolic blood pressure.
Figure. Lifetime cumulative incidence of PAD by race and sex.
ABI indicates ankle-brachial index; PAD, peripheral artery
disease.
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with a lifetime risk of 19%, and Hispanic men and women,
with a lifetime risk of 22%.
Residual Lifetime Risk of PAD by Traditional Risk
Factors
Even after accounting for other traditional risk factors, age
remained a strong predictor of PAD with an adjusted hazard
ratio of 1.47 (95% CI, 1.43–1.52) (Table 2). Again, women had
slightly higher odds of having an ABI <0.90 than men.
Compared with whites, blacks had higher odds and Hispanics
had lower odds of having PAD. All of the other traditional risk
factors—diabetes mellitus, smoking (both current and
former), systolic blood pressure, high-density lipoprotein
cholesterol, total cholesterol, and a history of other cardio-
vascular disease—demonstrated significant associations with
prevalent PAD.
On the basis of these estimates, we developed a calculator
for residual lifetime risk as well as probability of prevalent
PAD (http://ckdpcrisk.org/padrisk and every step is sum-
marized in Data S4). According to this calculator, we observed
a gradient of residual lifetime risk of PAD in the same race/
ethnicity exceeding 3.5- to 5-fold according to traditional risk
factors. For example, the residual risk varied from 19.9% to
70.4% in black men aged 45 years according to combinations
of smoking, diabetes mellitus, and history of cardiovascular
disease (Table 3). For an individual at age 65 years, because
of the shorter duration to 80 years of age, the residual
cumulative incidence was consistently lower than the sce-
nario for an individual at age 45 years, at a given combination
of traditional risk factors. Still, there was a 4- to 5.5-fold
gradient of residual lifetime risk of PAD according to smoking,
diabetes mellitus, and a history of coronary disease or stroke
within the same sex and race/ethnicity even in this scenario
of a 65-year-old individual.
Predicting Prevalent PAD by Traditional Risk
Factors
Using odds ratios of PAD according to traditional risk factors
in Table 2 as well as the prevalence of PAD in the
aforementioned base case in NHANES, we developed a
calculator to predict the probability of having PAD as well.
To cross-validate this approach, we split NHANES into 3
data sets (1999–2000, 2001–2002, and 2003–2004), devel-
oped a prediction model using 2 data sets, and compared
predicted versus observed using the remaining data set.
We indeed confirmed decent calibration (particularly in higher
risk groups with all P>0.1 in the top 5 deciles for 3
cross-validation scenarios) and discrimination (cross-validated
c-statistic=0.75) (Figure S2). To maximize available data for
best predicting the probability of having PAD, the final model
used the whole NHANES data, which demonstrated good
calibration (v2 of 10.2 with P=0.35) and discrimination
(c-statistic=0.77) (Figure S3). The variation of predicted
probability of having PAD in several scenarios is shown in
Table 4. The probability of having PAD within the same age,
sex, and race/ethnicity varied by 6- to 10-fold by smoking
status, diabetes mellitus, and a history of coronary disease or
stroke (eg, predicted probability from 1.2% to 10.5% in 45-
year-old black men).
Discussion
Using data from 6 US community-based cohorts, this study
reported lifetime risk estimation of PAD. In blacks, 30% of
men and women were estimated to develop PAD during their
lifetime, whereas in whites and Hispanics the corresponding
estimate is 20%. From another perspective, blacks reached
a 10% lifetime risk for PAD 8 to 11 years earlier than whites
and Hispanics. Women had a similar lifetime risk of PAD as
men in all racial/ethnic groups. As anticipated, smoking
(both current and former), diabetes mellitus, and a history of
other cardiovascular disease were particularly potent pre-
dictors of developing PAD, contributing to an 5-fold
gradient of residual lifetime risk and 10-fold gradient of
the probability of prevalent PAD at a given age, sex, and
race/ethnicity.
The higher lifetime risk of PAD in blacks compared with
whites and Hispanics in our study is consistent with
prevalence data shown in previous studies.27,28 It is possible
that this is partially explained by poor risk factor profiles in
blacks compared with the other 2 groups, but this pattern
Table 2. Adjusted Pooled OR of Having ABI <0.90
Variables Pooled OR (95% CI)
Age, 5 y 1.47 (1.43, 1.52)
Female 1.31 (1.19, 1.44)
Black 1.65 (1.48, 1.84)
Hispanic 0.78 (0.64, 0.94)
Diabetes mellitus 1.54 (1.38, 1.71)
Former smoker 1.50 (1.34, 1.67)
Current smoker 3.09 (2.74, 3.49)
SBP, 20 mm Hg 1.27 (1.22, 1.32)
HDL cholesterol, 1 mmol/L 0.68 (0.60, 0.76)
Total cholesterol, 1 mmol/L 1.14 (1.09, 1.19)
History of coronary disease or stroke 2.01 (1.81, 2.24)
All variables were modeled simultaneously. ABI indicates ankle-brachial index; HDL, high-
density lipoprotein; OR, odds ratio; SBP, systolic blood pressure.
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remained consistent even after accounting for key traditional
atherosclerotic risk factors in the present study (Table 2) as
well as in previous studies.29 In this context, a recent study
has demonstrated that socioeconomic factors such as
education, household income, and neighborhood deprivation
are associated with PAD risk beyond traditional risk factors.30
Nonetheless, although major guidelines for PAD did not
specify black race as a risk factor for PAD,19 our results
suggest the importance for healthcare providers to keep in
mind this disproportional risk of PAD in blacks.
We observed a slightly higher prevalence of PAD in women
than in men, particularly below 65 years of age (and similar
lifetime risk of PAD between women and men). This may seem
counterintuitive in light of epidemiology of other atheroscle-
rotic diseases such as coronary disease, but several previous
community-based studies report the same pattern for PAD
prevalence.27,31,32 Some reports suggest that this may be
partially explained by shorter height in women than in men,
potentially influencing ankle blood pressure.33,34 Importantly,
this cannot be simply interpreted as misclassification, as ABI
Table 3. Projected Residual Cumulative Incidence (%) of PAD
in the United States Across Different Scenarios of
Demographic and Clinical Factors
Demographic and clinical factors Male Female
Age 45 y
Whites
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 11.3 13.4
Diabetes mellitus 16.4 19.2
History of CHD or stroke
No diabetes mellitus 20.5 23.7
Diabetes mellitus 28.4 32.4
Current smoker
No history of CHD or stroke
No diabetes mellitus 28.4 32.4
Diabetes mellitus 37.8 42.4
History of CHD or stroke
No diabetes mellitus 44.4 49.1
Diabetes mellitus 55.0 59.7
Blacks
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 19.9 17.7
Diabetes mellitus 27.6 24.8
History of CHD or stroke
No diabetes mellitus 33.3 30.2
Diabetes mellitus 43.4 39.9
Current smoker
No history of CHD or stroke
No diabetes mellitus 43.4 39.9
Diabetes mellitus 54.1 50.5
History of CHD or stroke
No diabetes mellitus 60.7 57.2
Diabetes mellitus 70.4 67.2
Age 65 y
Whites
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 8.0 8.2
Diabetes mellitus 11.7 12.1
History of CHD or stroke
No diabetes mellitus 14.8 15.3
Diabetes mellitus 21.1 21.7
Continued
Table 3. Continued
Demographic and clinical factors Male Female
Current smoker
No history of CHD or stroke
No diabetes mellitus 21.1 21.7
Diabetes mellitus 29.1 29.8
History of CHD or stroke
No diabetes mellitus 35.0 35.8
Diabetes mellitus 45.3 46.1
Blacks
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 16.8 12.9
Diabetes mellitus 23.7 18.6
History of CHD or stroke
No diabetes mellitus 29.0 23.0
Diabetes mellitus 38.5 31.5
Current smoker
No history of CHD or stroke
No diabetes mellitus 38.5 31.5
Diabetes mellitus 49.0 41.4
History of CHD or stroke
No diabetes mellitus 55.8 48.1
Diabetes mellitus 66.0 58.7
Scenarios are all for a systolic blood pressure of 130 mmHg, high-density lipoprotein
cholesterol of 50 mg/dL, and total cholesterol of 200 mg/dL. CHD indicates coronary
heart disease; PAD, peripheral artery disease.
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<0.90 conferred a 2-fold higher risk of mortality as compared
with the reference category of 1.1 to 1.2 in both men and
women.8 Nonetheless, as the American Heart Association
called for action,35 further studies are need for PAD in women,
including investigations of its similar burden between men
and women. In this context, it will be important to evaluate
lifetime risk specifically for severe types of PAD requiring leg
revascularization or amputation in both sexes.
There seem to be a few ways to use the risk calculators
from this study. For example, our lifetime risk calculator can
be complementary to the American Heart Association/
American College of Cardiology lifetime risk calculator for
coronary disease and stroke7 and may contribute to compre-
hensive cardiovascular risk assessment. Importantly, the
awareness of PAD is low, and most PAD patients do not
have typical leg symptoms of intermittent claudication.17
Also, diagnostic processes and signs/symptoms are unique
for PAD (eg, leg examination, ABI measurement, and reduced
leg pulse). Thus, identifying people at high lifetime risk of PAD
may have implications on targeted patients’ education about
Table 4. Estimated Probability of Prevalent PAD (%) in the
United States Across Different Scenarios of Demographic and
Clinical Factors
Demographic and clinical factors Male Female
Age 45 y
Whites
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 0.6 1.4
Diabetes mellitus 0.9 2.1
History of CHD or stroke
No diabetes mellitus 1.2 2.7
Diabetes mellitus 1.8 4.1
Current smoker
No history of CHD or stroke
No diabetes mellitus 1.8 4.1
Diabetes mellitus 2.8 6.2
History of CHD or stroke
No diabetes mellitus 3.6 8.0
Diabetes mellitus 5.5 11.8
Blacks
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 1.2 1.8
Diabetes mellitus 1.8 2.8
History of CHD or stroke
No diabetes mellitus 2.4 3.6
Diabetes mellitus 3.6 5.5
Current smoker
No history of CHD or stroke
No diabetes mellitus 3.6 5.5
Diabetes mellitus 5.5 8.2
History of CHD or stroke
No diabetes mellitus 7.1 10.4
Diabetes mellitus 10.5 15.2
Age 65 y
Whites
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 2.7 4.3
Diabetes mellitus 4.1 6.4
History of CHD or stroke
No diabetes mellitus 5.3 8.2
Diabetes mellitus 7.9 12.1
Continued
Table 4. Continued
Demographic and clinical factors Male Female
Current smoker
No history of CHD or stroke
No diabetes mellitus 7.9 12.1
Diabetes mellitus 11.7 17.5
History of CHD or stroke
No diabetes mellitus 14.8 21.7
Diabetes mellitus 21.1 29.9
Blacks
Nonsmoker
No history of CHD or stroke
No diabetes mellitus 6.6 6.9
Diabetes mellitus 9.8 10.3
History of CHD or stroke
No diabetes mellitus 12.4 13.1
Diabetes mellitus 17.9 18.8
Current smoker
No history of CHD or stroke
No diabetes mellitus 17.9 18.8
Diabetes mellitus 25.1 26.2
History of CHD or stroke
No diabetes mellitus 30.5 31.7
Diabetes mellitus 40.3 41.7
Scenarios are all for a systolic blood pressure of 130 mmHg, high-density lipoprotein
cholesterol of 50 mg/dL, and total cholesterol of 200 mg/dL. CHD indicates coronary
heart disease; PAD, peripheral artery disease.
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manifestation and complications of PAD. The risk calculator
for prevalent PAD may have implications for screening PAD.
Although it is still under debate,19,36 some guidelines
recommend screening PAD using ABI among high-risk
individuals.19 Although those clinical guidelines empirically
rely on age and the presence of a few key risk factors to
identify “high-risk” populations for PAD (eg, all adults aged
≥65 years or people aged 50 to 64 years with any
atherosclerotic risk factors19), our risk calculator for prevalent
PAD will allow healthcare providers and patients to quantify
the risk objectively on the basis of a combination of risk
factors.
Although we tried to use the best readily available data in
the United States, we need to acknowledge several limita-
tions. First, most data were collected in the 1990s or early
2000s, and, unfortunately, few contemporary US community-
based cohorts measured ABI in multiple racial/ethnic groups.
Since a recent international study reported that the preva-
lence of PAD increased by 13% in high-income countries from
2000 to 2010,32 our estimates may be conservative. On the
other hand, the increase in prevalent PAD may be
attributable to improved survival in people with PAD rather
than an increased incidence, and thus a follow-up investiga-
tion with contemporary data would be important. Also, we
cannot deny the possibility of birth cohort effects on
prevalence of PAD. Second, we could not reliably estimate
lifetime risk of PAD over the age of 80 years because of
sparse data in this age range in our data sets (eg, NHANES
coded all ages older than 80 as age 80). Given extending life
expectancy in the United States, this is another element
indicating that our estimates are likely to be conservative.
Third, as anticipated from the literature,37 the mortality rate
in our cohorts tended to be lower than the mortality rate
from vital statistics (Table S5). However, our lifetime risk
estimation is based on the mortality rate from vital statistics
and relative risk from 6 US cohorts. Of note, cardiovascular
relative risk of many risk factors including ABI has been
shown to be often consistent regardless of the baseline risk
of study populations.8,38 Fourth, we did not have systematic
data regarding history of leg revascularization across cohorts,
indicating some level of underestimation by not capturing
some PAD cases with ABI >0.90 after vascular procedures.
Fifth, a few cohorts did not have granular data of smoking
status. Sixth, as true for almost any diagnostic tests, ABI is
validated to diagnose PAD but is not perfect (sensitivity and
specificity >90%–95% in various studies39–42). For example, a
high ABI may mask PAD in some individuals.43 Finally,
although our data consisted of the 3 major racial/ethnic
groups in the United States, data for other racial/ethnic
groups were lacking.
In conclusion, 30% of blacks are estimated to develop
PAD during their lifetime, whereas the estimate is 20% for
whites and Hispanics. Unlike other atherosclerotic diseases,
lifetime risk and the prevalence of PAD based on ABI <0.90
was similar in women and in men. Among traditional
atherosclerotic risk factors, age, smoking, and diabetes
mellitus as well as a history of coronary disease or stroke
are confirmed to be potent predictors of PAD risk and
contributed to substantial variation of lifetime risk of PAD
within the same race/ethnicity.
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SUPPLEMENTAL MATERIAL 
 
Data S1. State transition probabilities. 
 
Markov chain model used to simulate the progression of an individual free of peripheral artery 
disease (PAD) through death or the development of PAD. 
 
 
Terms of symbols in the formula 
Px --- prevalence of PAD at a given age, sex and race/ethnicity (from section “Estimating the 
prevalence of PAD”) 
Px+1 --- prevalence of PAD at the next year of age as for P1x (from section “Estimating the 
prevalence of PAD”) 
HRx --- hazard ratios of mortality for PAD vs. no PAD at a given age, sex and race/ethnicity 
(from section “Estimating the relative risk of mortality for PAD vs. no PAD”)  
Qx --- annual probability of death for the US population at a given age, sex and race/ethnicity 
(from National Vital Statistics Report) 
Q0x (QnoPAD) --- 1-year probability of dying among persons free of PAD at a given age, sex and 
race/ethnicity 
Q1x (QPAD) --- 1-year probability of dying among persons with PAD at a given age, sex and 
race/ethnicity 
RRx --- risk ratios of mortality for PAD vs. no PAD at a given age, sex and race/ethnicity  
Ix (IPAD) --- the probability of developing PAD at a given age, sex race/ethnicity 
Step 1: calculate Q0x. This approach is based on the fact that annual overall mortality can be 
viewed as weighted average of 1-year probability of dying among persons with PAD and that of 
those without PAD 
From Cox survival model 
Q1x = 1 – (1 – Q0x) ^HRx    (1) 
RRx = Q1x / Q0x = (1 – (1 – Q0x) ^HRx) / Q0x   (2) 
Qx = (1 – Px) Q0x + Px Q1x = (1 – Px) Q0x + P1x RRx Q0x = (1 – Px + Px RRx) Q0x   (3) 
Q0x = Qx / (1 – Px + Px RRx)   (4) 
Since we do not know RRx, we used iterations to approximate RRx. 
From equation (2) above, the limit of RRx of Q0x as Q0x approaches 0 equals HRx. So we used 
HRx as the beginning value of RRx. During iterations, we first used equation (4) and RRx from 
the previous iteration to get Q0x of the current iteration. Then we used equation (2) to get RRx of 
the current iteration. The iterations were stopped until the difference of Q0x between current and 
previous iteration was less than 1E-8. 
Step 2: calculate Ix. This approach is based on the fact that the prevalence of no PAD at age of 
x+1 is determined by four elements, the prevalence of no PAD at age of x, two types of exits 
from no PAD, annual incidence of PAD during age of x or mortality among no PAD during age of 
x, and annual mortality of the population. 
1 – Px+1 = (1 – Px) (1 – Ix – Q0x) / (1-Qx)   (5) 
1 – Ix – Q0x = (1 – Px+1) (1-Qx) / (1 – Px)   (6) 
Ix = 1– Q0x – (1 – Px+1) (1-Qx) / (1 – Px)     (7) 
 
The scheme below depicts how we obtained IPAD,x. 
 
Data S2. Methods for measuring ABI in each cohort. 
 
ARIC: The ABI was measured by Dinamap Model 1846 SX, an oscillometric device.1 Ankle 
systolic blood pressure was measured a maximum of four times in a randomly selected single 
leg, and the last measurement was used for ABI. Brachial systolic blood pressure was 
measured twice, and the first measurement was used.  
FHS and FOF: The ABI was measured using an 8-MHz Doppler probe and an ultrasonic 
Doppler flow detector (Parks Medical Electronics Inc, Shaw Aloha, Oregon).2, 3 Systolic blood 
pressure was measured twice on both arms and both ankles. When the first two blood pressure 
values were different by >10 mmHg at any site, a third measurement was performed. When the 
posterior tibial pulse was not located, measurement was conducted at the dorsalis pedis artery. 
The ABI was calculated for each leg as the average ankle systolic blood pressure divided by the 
average systolic blood pressure of the higher arm.  
MESA: The ABI was measured by a handheld Doppler instrument with a 5-MHz probe.4 Systolic 
blood pressure was measured at the right and left brachial, dorsalis pedis, and posterior tibial 
arteries. The higher value of brachial artery pressure was used as the denominator of ABI. The 
higher pressure from dorsalis pedis or posterior tibial was used as the numerator of ABI for each 
leg, and the smaller value between right or left was recorded.  
NHANES: Systolic blood pressure was measured on the right arm (left arm was used if there 
were any conditions on the right arm that would interfere with blood pressure measurement) and 
bilateral posterior tibial arteries.5 The measurements were done twice among participants aged 
40-59 years and once in participants aged 60 years or older. ABI was calculated for each leg by 
dividing the average systolic blood pressure in the ankle by the average blood pressure in the 
arm, and the smaller value was recorded.  
Data S3. Residual lifetime cumulative incidence by traditional atherosclerotic risk factors.  
 
Lifetime cumulative incidence estimates at a given age, sex and race/ethnicity can be viewed as 
a weighted average of residual lifetime risk of subgroups determined by combinations of the 
presence and absence (or higher and lower values if continuous factors) of traditional risk 
factors at that given age, sex and race/ethnicity. Using sample weights and actual values of 
traditional risk factors in NHANES, we first estimated lifetime cumulative incidence for a 
hypothetical person at a given age, sex and race/ethnicity, as well as traditional risk factors. 
Terms of symbols in the formula 
Rx --- Lifetime cumulative incidence estimates of PAD at a given age, sex and race/ethnicity 
(from section “Lifetime accumulative incidence estimation”) 
Rx0 --- Lifetime cumulative incidence estimates of PAD at a given age, sex and race/ethnicity for 
a hypothetical person with given values of traditional risk factors (no diabetes, nonsmoker, 
systolic blood pressure 120 , high-density lipoprotein cholesterol 60mg/dL, total cholesterol 200 
mg/dL and no history of CHD or stroke) 
Rxi --- Lifetime cumulative incidence estimates of PAD at a given age, sex and race/ethnicity for 
a real individual in NHANES with actual values of traditional risk factors  
ORxi --- odds ratios of PAD for a real individual in NHANES compared to the hypothetical person 
at the same sex and race/ethnicity group and within 5 year of age (from section “Estimating 
relative risk of PAD for traditional risk factors”, combined with difference between actual value of 
the individual and the given value of the hypothetical person for each risk factor as well as age)  
Wxi --- sample weight for a real individual in NHANES at the same sex and race/ethnicity group 
and within 5 year of age 
TW --- total sample weight for real individuals in NHANES at the same sex and race/ethnicity 
group and within 5 year of age 
RRxi --- risk ratios of PAD for a real individual in NHANES compared to the hypothetical person 
at the same sex and race/ethnicity group and within 5 year of age. 
From logistic model 
Rxi = Rx0 ORxi / (1 – Rx0 + Rx0 ORxi)   (8) 
RRxi = Rxi / Rx0 = ORxi / (1 – Rx0 + Rx0 ORxi)   (9) 
Rx = sum of i (Rxi Wxi / TW) = sum of i (RRxi Rx0 Wxi / TW) = sum of i (RRxi Wxi) Rx0 / TW (10) 
Rx0 = Rx TW / sum of i (RRxi Wxi)   (11) 
Since we do not know RRxi, we used iterations to approximate RRxi. 
From equation (9) above, RRxi approximately equals ORxi when Rx0 is very small. So we used 
ORxi as the beginning value of RRxi. During iterations, we first used equation (11) and RRxi from 
the previous iteration to get Rx0 of the current iteration. Then we used equation (9) to get RRxi of 
the current iteration. The iterations were stopped until the difference of Rx0 between current and 
previous iteration was less than 1E-8. 
By using equation (9) above, we can estimate residual lifetime cumulative incidence for 
scenarios with combinations of any traditional risk factors.
Data S4. Project an Individual’s residual cumulative incidence (%) of PAD in the United 
States. 
 
Step 1: Calculate linear function (B) for individual participant  
B = 0.1194242 × (SBP – 120) /10  – 0.3924322 × (HDLC – 1.5516) + 0.1301318 × (Tchol – 
5.172) + 0.4291214 (if diabetes) + 0.4024582 (if former smoker) + 1.129064 (if current 
smoker) + 0.6998957 (if history of CVD) 
Step 2: Use the Lifetime Risk (%) for given age, sex, and race x (Hx) 
Age 
Group 
White Man White 
Woman 
Black Man Black 
Woman 
Hispanic 
Man 
Hispanic  
Woman 
40-44 10.996 13.045 16.922 16.335 10.601 14.178 
45-49 9.307 11.033 16.605 14.678 9.197 13.352 
50-54 8.760 9.401 14.730 16.944 11.227 13.878 
55-59 8.473 9.359 18.222 15.068 8.584 12.654 
60-64 6.917 7.287 13.709 12.058 8.655 10.319 
65-69 6.481 6.698 13.971 10.647 10.156 8.857 
70-74 5.575 5.087 11.872 6.764 7.181 6.090 
75-79 3.754 3.554 8.821 4.716 5.007 4.547 
 
Step 3: Project residual cumulative incidence (%) for an individual  
Residual cumulative incidence (%) = Hx × exp(B) / (100 + Hx × (exp(B) – 1)) × 100 
 
Table S1. Baseline study characteristics by sex. 
 
Male Study 
  ARIC (6517) CHS (2428) FHS (221) FOF (1650) MESA (3199) 
NHANES 
(3748) 
Total of death - N (%) 2366 (36%) 2123 (87%) 173 (78%) 239 (14%) 653 (20%) 895 (24%) 
Follow-up time (y) - Mean(SD) 18 (5.6) 12 (6.5) 8.4 (4.0) 10 (2.2) 12 (2.7) 8.8 (2.7) 
Age (y) - Mean (SD) 55 (5.9) 73 (5.7) 79 (3.9) 59 (9.7) 62 (10) 60 (13) 
Race/Ethnicity - N (%) 
      
 White 5121 (79%) 2092 (86%) 221 (100%) 1650 (100%) 1255 (39%) 2124 (57%) 
 Black  1396 (21%) 319 (13%) - - 835 (26%) 691 (18%) 
 Hispanic - 17 (0.70%) - - 1109 (35%) 933 (25%) 
Smoking Status - N (%) 
      
 Never 1798 (28%) 772 (32%) 212 (96%) 1408 (85%) 1296 (41%) 1020 (27%) 
 Former 2938 (45%) 1386 (57%) - - 1438 (45%) 2252 (60 %) 
 Current 1781 (27%) 270 (11%) 9 (4.1%) 242 (15%) 465 (15%) 473 (13%) 
SBP (mmHg) - Mean (SD) 122 (18) 136 (21) 143 (22) 129 (17) 126 (19) 130 (19) 
Total cholesterol (mmol/L) - 
Mean(SD) 5.5 (1.0) 5.1 (0.9) 5.0 (0.8) 5.1 (1.0) 4.6 (0.9) 5.3 (1.1) 
HDL cholesterol (mmol/L) - Mean(SD) 1.1 (0.4) 1.2 (0.3) 1.1 (0.4) 1.1 (0.3) 1.2 (0.3) 1.2 (0.4) 
Diabetes - N (%) 735 (11%) 416 (17%) 58 (26%) 195 (12%) 444 (14%) 659 (18%) 
History of CHD or stroke - N (%) 878 (13%) 505 (21%) 74 (33%) 156 (9.5%) 3 (0.09%) 576 (15%) 
ABI - Mean (SD) 1.16 (0.14) 1.08 (0.20) 1.04 (0.23) 1.14 (0.13) 1.14 (0.13) 1.11 (0.16) 
PAD (ABI <0.90) - N (%) 220 (3.4%) 359 (15%) 48 (22%) 56 (3.4%) 121 (3.8%) 312 (8.3%) 
 
 
Female Study 
  ARIC (7757) CHS (3234) FHS (376) FOF (1870) MESA (3573) 
NHANES 
(3581) 
Total of death - N (%) 1906 (25%) 2485 (77%) 257 (68%) 141 (7.5%) 491 (14%) 621 (17%) 
Follow-up time (y) - Mean(SD) 19 (4.8) 14 (6.3) 9.4 (3.8) 10 (1.9) 13 (2.3) 9.2 (2.5) 
Age (y) - Mean (SD) 54 (5.9) 72 (5.4) 80 (3.9) 58 (9.5) 62 (10) 60 (13) 
Race/Ethnicity - N (%) 
      
 White 5598 (72%) 2698 (83%) 376 (100%) 1870 (100%) 1359 (38%) 1968 (55%) 
 Black  2159 (28%) 518 (16%) - - 1033 (29%) 670 (19%) 
 Hispanic - 18 (0.56%) - - 1181 (33%) 943 (26%) 
Smoking Status - N (%) 
      
 Never 4065 (52%) 1843 (57%) 345 (92%) 1569 (84%) 2107 (59%) 2043 (57%) 
 Former 1761 (23%) 983 (30%) - - 1051 (29%) 1040 (29%) 
 Current 1931 (25%) 408 (13%) 31 (8.2%) 301 (16%) 415 (12%) 494 (14%) 
SBP (mmHg) - Mean (SD) 120 (20) 137 (22) 143 (21) 126 (19) 127 (23) 133 (23) 
Total cholesterol (mmol/L) - 
Mean(SD) 5.6 (1.1) 5.7 (1.0) 5.5 (1.0) 5.5 (1.0) 5.2 (0.9) 5.5 (1.0) 
HDL cholesterol (mmol/L) - Mean(SD) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4) 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) 
Diabetes - N (%) 844 (11%) 421 (13%) 72 (19%) 141 (7.5%) 404 (11%) 541 (15%) 
History of CHD or stroke - N (%) 918 (12%) 388 (12%) 62 (16%) 65 (3.5%) 2 (0.06%) 338 (9.4%) 
ABI - Mean (SD) 1.11 (0.14) 1.05 (0.15) 0.99 (0.19) 1.08 (0.10) 1.09 (0.11) 1.07 (0.15) 
PAD (ABI <0.90) - N (%) 414 (5.3%) 400 (12%) 76 (20%) 56 (3.0%) 134 (3.8%) 321 (9.0%) 
 
SD: standard deviation; SBP: systolic blood pressure; HDL: high-density lipoprotein; ABI: ankle-brachial index; PAD: peripheral artery 
disease
Table S2. Odds ratio of PAD (ABI <0.9) according to demographic factors from the pooled 
data of six US cohorts. 
 
Demographic variables Odds ratios for ABI<0.9 
Age for White and Black male, per 5y 1.56 (1.50, 1.61) 
Female at age 65 for Whites 1.24 (1.12, 1.38) 
Black for male 2.16 (1.86, 2.52) 
Hispanic at age 65 for male 0.76 (0.62, 0.93) 
Age * female, per 5y 0.90 (0.86, 0.94) 
Age * Hispanic, per 5y 1.16 (1.06, 1.27) 
Female * Black 0.77 (0.63, 0.94) 
 
All variables listed were modeled simultaneously. 
Table S3. Sex- and race/ethnicity-adjusted hazard ratios (95% CIs) for mortality according 
to PAD (ABI <0.9) vs. no PAD (ABI ≥0.9) 
 
Characteristic HR (95% CIs) 
Low ABI at age 65 2.43 (2.18, 2.72) 
Low ABI * age with age<65, per 5y 1.09 (1.00, 1.18) 
Low ABI * age with age≥65, per 5y 0.87 (0.83, 0.92) 
 
All variables listed were modeled simultaneously. 
 
 
Table S4. Estimated QnoPAD (1-year probability of dying among persons of a given age, sex, and race/ethnicity and free of 
PAD) and IPAD (the probability of developing PAD at a given age) at each age from birth to 80 years in each sex and 
racial/ethnic group.  
White men White women Black men Black women Hispanic men Hispanic women 
Age QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x 
0 0.0060382 0.0000224 0.0049966 0.0000843 0.0139084 0.0000534 0.0114623 0.0001567 0.0060643 0.0000032 0.0050652 0.0000130 
1 0.0004640 0.0000227 0.0003913 0.0000827 0.0007636 0.0000492 0.0005462 0.0001385 0.0004421 0.0000034 0.0003704 0.0000135 
2 0.0002985 0.0000247 0.0002167 0.0000881 0.0004622 0.0000535 0.0003487 0.0001476 0.0002846 0.0000039 0.0001887 0.0000148 
3 0.0002337 0.0000270 0.0001573 0.0000941 0.0003470 0.0000584 0.0003214 0.0001577 0.0001934 0.0000043 0.0001619 0.0000163 
4 0.0001671 0.0000294 0.0001427 0.0001006 0.0003105 0.0000637 0.0002063 0.0001682 0.0001723 0.0000049 0.0001383 0.0000180 
5 0.0001565 0.0000322 0.0001248 0.0001076 0.0002693 0.0000696 0.0001894 0.0001798 0.0001467 0.0000055 0.0001203 0.0000198 
6 0.0001400 0.0000351 0.0001138 0.0001150 0.0002516 0.0000760 0.0001582 0.0001921 0.0001289 0.0000062 0.0001081 0.0000218 
7 0.0001247 0.0000384 0.0001052 0.0001229 0.0002293 0.0000830 0.0001376 0.0002053 0.0001123 0.0000069 0.0001002 0.0000241 
8 0.0001055 0.0000419 0.0000965 0.0001314 0.0001909 0.0000906 0.0001260 0.0002195 0.0000921 0.0000078 0.0000954 0.0000265 
9 0.0000837 0.0000457 0.0000878 0.0001405 0.0001394 0.0000989 0.0001226 0.0002346 0.0000692 0.0000088 0.0000937 0.0000292 
10 0.0000684 0.0000500 0.0000821 0.0001502 0.0000945 0.0001079 0.0001278 0.0002509 0.0000519 0.0000099 0.0000958 0.0000322 
11 0.0000756 0.0000546 0.0000852 0.0001606 0.0000901 0.0001179 0.0001428 0.0002683 0.0000557 0.0000111 0.0001033 0.0000355 
12 0.0001238 0.0000597 0.0001036 0.0001718 0.0001644 0.0001289 0.0001687 0.0002869 0.0000996 0.0000125 0.0001185 0.0000391 
13 0.0002216 0.0000653 0.0001402 0.0001838 0.0003333 0.0001411 0.0002048 0.0003070 0.0001949 0.0000141 0.0001420 0.0000431 
14 0.0003528 0.0000714 0.0001885 0.0001967 0.0005609 0.0001546 0.0002471 0.0003284 0.0003287 0.0000159 0.0001714 0.0000475 
15 0.0004888 0.0000782 0.0002412 0.0002105 0.0007961 0.0001695 0.0002919 0.0003514 0.0004750 0.0000180 0.0002050 0.0000523 
16 0.0006165 0.0000855 0.0002894 0.0002253 0.0010067 0.0001857 0.0003363 0.0003759 0.0006159 0.0000202 0.0002375 0.0000577 
17 0.0007456 0.0000936 0.0003290 0.0002410 0.0012031 0.0002033 0.0003806 0.0004022 0.0007552 0.0000228 0.0002642 0.0000636 
18 0.0008759 0.0001024 0.0003567 0.0002578 0.0013860 0.0002227 0.0004264 0.0004303 0.0008895 0.0000257 0.0002825 0.0000701 
19 0.0010050 0.0001121 0.0003762 0.0002757 0.0015626 0.0002438 0.0004753 0.0004604 0.0010173 0.0000290 0.0002946 0.0000772 
20 0.0011433 0.0001227 0.0003953 0.0002949 0.0017594 0.0002670 0.0005314 0.0004926 0.0011544 0.0000327 0.0003057 0.0000851 
21 0.0012718 0.0001342 0.0004165 0.0003154 0.0019565 0.0002924 0.0005905 0.0005271 0.0012811 0.0000368 0.0003183 0.0000938 
22 0.0013553 0.0001468 0.0004351 0.0003373 0.0020987 0.0003199 0.0006429 0.0005640 0.0013514 0.0000415 0.0003299 0.0001033 
23 0.0013763 0.0001604 0.0004506 0.0003606 0.0021539 0.0003496 0.0006812 0.0006032 0.0013446 0.0000467 0.0003399 0.0001139 
24 0.0013519 0.0001751 0.0004637 0.0003856 0.0021411 0.0003817 0.0007082 0.0006449 0.0012869 0.0000525 0.0003483 0.0001255 
25 0.0013129 0.0001911 0.0004772 0.0004123 0.0021021 0.0004166 0.0007343 0.0006896 0.0012171 0.0000590 0.0003576 0.0001382 
26 0.0012838 0.0002086 0.0004921 0.0004408 0.0020757 0.0004547 0.0007659 0.0007373 0.0011620 0.0000664 0.0003666 0.0001523 
27 0.0012646 0.0002278 0.0005073 0.0004713 0.0020680 0.0004964 0.0008011 0.0007884 0.0011209 0.0000747 0.0003724 0.0001678 
28 0.0012644 0.0002488 0.0005239 0.0005039 0.0020970 0.0005422 0.0008440 0.0008431 0.0011004 0.0000841 0.0003743 0.0001849 
 
White men White women Black men Black women Hispanic men Hispanic women 
Age QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x 
29 0.0012809 0.0002718 0.0005439 0.0005388 0.0021585 0.0005925 0.0008969 0.0009017 0.0010957 0.0000946 0.0003752 0.0002037 
30 0.0013052 0.0002969 0.0005700 0.0005762 0.0022380 0.0006475 0.0009625 0.0009645 0.0010937 0.0001065 0.0003758 0.0002244 
31 0.0013319 0.0003243 0.0006035 0.0006162 0.0023173 0.0007077 0.0010386 0.0010319 0.0010919 0.0001198 0.0003822 0.0002472 
32 0.0013633 0.0003543 0.0006420 0.0006590 0.0024199 0.0007736 0.0011237 0.0011041 0.0010792 0.0001348 0.0003976 0.0002723 
33 0.0014067 0.0003872 0.0006875 0.0007048 0.0024507 0.0008447 0.0012012 0.0011811 0.0011309 0.0001518 0.0004378 0.0003002 
34 0.0014546 0.0004231 0.0007357 0.0007538 0.0024994 0.0009226 0.0012825 0.0012634 0.0011744 0.0001710 0.0004881 0.0003308 
35 0.0015152 0.0004623 0.0007896 0.0008063 0.0025566 0.0010076 0.0013684 0.0013515 0.0012266 0.0001925 0.0005467 0.0003647 
36 0.0015917 0.0005053 0.0008520 0.0008626 0.0026413 0.0011009 0.0014700 0.0014460 0.0012897 0.0002168 0.0006083 0.0004020 
37 0.0016831 0.0005525 0.0009244 0.0009229 0.0027590 0.0012032 0.0015956 0.0015477 0.0013744 0.0002441 0.0006733 0.0004431 
38 0.0017931 0.0006041 0.0010105 0.0009876 0.0029212 0.0013156 0.0017535 0.0016574 0.0014851 0.0002750 0.0007402 0.0004884 
39 0.0019260 0.0006607 0.0011116 0.0010570 0.0031279 0.0014393 0.0019419 0.0017756 0.0016183 0.0003099 0.0008113 0.0005384 
40 0.0020736 0.0007227 0.0012201 0.0011315 0.0033660 0.0015750 0.0021443 0.0019025 0.0017709 0.0003493 0.0008882 0.0005935 
41 0.0022445 0.0007908 0.0013391 0.0012113 0.0036306 0.0017240 0.0023579 0.0020387 0.0019347 0.0003936 0.0009758 0.0006543 
42 0.0024567 0.0008657 0.0014791 0.0012971 0.0039327 0.0018876 0.0025970 0.0021853 0.0021018 0.0004436 0.0010788 0.0007214 
43 0.0027111 0.0009481 0.0016388 0.0013895 0.0042697 0.0020675 0.0028596 0.0023431 0.0022656 0.0004999 0.0011998 0.0007955 
44 0.0029929 0.0010388 0.0018088 0.0014885 0.0046392 0.0022649 0.0031371 0.0025125 0.0024302 0.0005633 0.0013354 0.0008773 
45 0.0032796 0.0011380 0.0019808 0.0015945 0.0050127 0.0024808 0.0034143 0.0026937 0.0026051 0.0006348 0.0014803 0.0009675 
46 0.0035701 0.0012466 0.0021511 0.0017077 0.0054195 0.0027179 0.0036944 0.0028875 0.0028008 0.0007154 0.0016308 0.0010670 
47 0.0038829 0.0013658 0.0023230 0.0018289 0.0059230 0.0029806 0.0039956 0.0030958 0.0030221 0.0008064 0.0017885 0.0011767 
48 0.0042294 0.0014969 0.0025008 0.0019586 0.0065616 0.0032736 0.0043302 0.0033203 0.0032787 0.0009093 0.0019546 0.0012977 
49 0.0046108 0.0016412 0.0026893 0.0020976 0.0073193 0.0035996 0.0046969 0.0035623 0.0035729 0.0010254 0.0021313 0.0014311 
50 0.0050250 0.0017997 0.0028966 0.0022470 0.0081400 0.0039596 0.0050937 0.0038230 0.0038966 0.0011567 0.0023275 0.0015784 
51 0.0054540 0.0019737 0.0031166 0.0024071 0.0089777 0.0043546 0.0054976 0.0041021 0.0042487 0.0013048 0.0025373 0.0017408 
52 0.0058863 0.0021641 0.0033389 0.0025784 0.0098475 0.0047887 0.0058881 0.0043992 0.0046412 0.0014723 0.0027448 0.0019196 
53 0.0063126 0.0023721 0.0035593 0.0027612 0.0107327 0.0052643 0.0062480 0.0047139 0.0050751 0.0016617 0.0029394 0.0021160 
54 0.0067439 0.0025997 0.0037875 0.0029569 0.0116324 0.0057851 0.0065891 0.0050478 0.0055457 0.0018756 0.0031267 0.0023317 
55 0.0071995 0.0028493 0.0040285 0.0031665 0.0126175 0.0063601 0.0069414 0.0054048 0.0060732 0.0021177 0.0033222 0.0025692 
56 0.0077006 0.0031239 0.0043064 0.0033925 0.0136499 0.0069919 0.0073299 0.0057884 0.0066381 0.0023913 0.0035436 0.0028310 
57 0.0082524 0.0034261 0.0046479 0.0036379 0.0146019 0.0076739 0.0077575 0.0062010 0.0071853 0.0026989 0.0037959 0.0031199 
58 0.0088623 0.0037590 0.0050702 0.0039056 0.0154138 0.0084032 0.0082455 0.0066470 0.0076792 0.0030435 0.0040906 0.0034389 
59 0.0095266 0.0041256 0.0055632 0.0041969 0.0161333 0.0091859 0.0088041 0.0071303 0.0081361 0.0034297 0.0044293 0.0037913 
60 0.0102477 0.0045293 0.0061153 0.0045131 0.0168518 0.0100342 0.0094446 0.0076552 0.0085940 0.0038633 0.0048068 0.0041803 
61 0.0110167 0.0049731 0.0067012 0.0048541 0.0176850 0.0109664 0.0101553 0.0082236 0.0091131 0.0043522 0.0052209 0.0046094 
 
White men White women Black men Black women Hispanic men Hispanic women 
Age QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x QnoPAD,x IPAD,x 
62 0.0118283 0.0054606 0.0073075 0.0052206 0.0186714 0.0119955 0.0109087 0.0088352 0.0097311 0.0049049 0.0056814 0.0050830 
63 0.0126917 0.0059964 0.0079283 0.0056138 0.0198587 0.0131373 0.0116616 0.0094862 0.0105013 0.0055323 0.0061945 0.0056060 
64 0.0136353 0.0065873 0.0085877 0.0060379 0.0212007 0.0143965 0.0124078 0.0101778 0.0114238 0.0062445 0.0067682 0.0061839 
65 0.0147176 0.0072435 0.0093504 0.0065019 0.0226730 0.0157796 0.0132002 0.0109203 0.0124666 0.0070506 0.0074245 0.0068238 
66 0.0160049 0.0079061 0.0102757 0.0069601 0.0243399 0.0170951 0.0141728 0.0116198 0.0136317 0.0079138 0.0081928 0.0074993 
67 0.0174127 0.0086245 0.0112766 0.0074467 0.0259332 0.0184635 0.0152008 0.0123524 0.0148693 0.0088727 0.0090175 0.0082349 
68 0.0188965 0.0093973 0.0123221 0.0079586 0.0273930 0.0198724 0.0163035 0.0131210 0.0161176 0.0099304 0.0098661 0.0090312 
69 0.0204738 0.0102279 0.0134457 0.0084996 0.0287685 0.0213276 0.0175170 0.0139308 0.0173635 0.0110932 0.0107413 0.0098919 
70 0.0221607 0.0111198 0.0146714 0.0090724 0.0300198 0.0228187 0.0187703 0.0147688 0.0186248 0.0123694 0.0116419 0.0108198 
71 0.0241157 0.0120897 0.0161474 0.0096932 0.0314385 0.0243945 0.0200805 0.0156364 0.0199747 0.0137721 0.0126443 0.0118253 
72 0.0264680 0.0131521 0.0178453 0.0103582 0.0334119 0.0261226 0.0217066 0.0165750 0.0214678 0.0153135 0.0138401 0.0129205 
73 0.0291013 0.0142969 0.0197306 0.0110628 0.0357968 0.0279724 0.0236453 0.0175806 0.0231860 0.0170080 0.0153101 0.0141170 
74 0.0319259 0.0155148 0.0217536 0.0118001 0.0388376 0.0299813 0.0258418 0.0186399 0.0251324 0.0188624 0.0170373 0.0154157 
75 0.0349096 0.0168013 0.0239242 0.0125695 0.0424434 0.0321215 0.0282534 0.0197410 0.0271593 0.0208667 0.0188975 0.0168052 
76 0.0381151 0.0181601 0.0263736 0.0133823 0.0460587 0.0342791 0.0307084 0.0208507 0.0294029 0.0230360 0.0208046 0.0182762 
77 0.0418193 0.0196147 0.0291561 0.0142405 0.0501478 0.0365214 0.0336099 0.0220262 0.0320727 0.0253914 0.0229083 0.0198430 
78 0.0461280 0.0211697 0.0324286 0.0151552 0.0546033 0.0388095 0.0369800 0.0232601 0.0353255 0.0279459 0.0253269 0.0215153 
79 0.0511228 0.0228234 0.0361976 0.0161199 0.0592316 0.0410888 0.0400724 0.0244320 0.0392497 0.0307010 0.0281402 0.0232964 
80 0.0564387 0.0245285 0.0402896 0.0171093 0.0641786 0.0433605 0.0437745 0.0256629 0.0436807 0.0336254 0.0312835 0.0251719 
 
 
Table S5. 1-year probability of dying among those with ABI >0.9 by age categories. 
 
Age, 
years 
QnoPAD,x  
MCMC 
model 
Mortality rate in cohort 
ARIC CHS FHS FOF MESA NHANES 
White men 
      
45 0.0032795 0.0021880 0.0009498 0.0011324 0.0005746 0.0004181 0.0016187 
55 0.0071989 0.0057350 0.0024921 0.0029707 0.0015080 0.0010976 0.0038198 
65 0.0147150 0.0149888 0.0065306 0.0077816 0.0039548 0.0028795 0.0090004 
75 0.0349024 0.0425772 0.0186995 0.0222554 0.0113516 0.0082735 0.0211321 
White women 
      
45 0.0019808 0.0014211 0.0006168 0.0007354 0.0003731 0.0002715 0.0010181 
55 0.0040288 0.0037273 0.0016188 0.0019298 0.0009793 0.0007128 0.0024036 
65 0.0093520 0.0097574 0.0042450 0.0050592 0.0025695 0.0018705 0.0056688 
75 0.0239289 0.0278543 0.0121811 0.0145066 0.0073849 0.0053795 0.0133401 
Black men 
      
45 0.0050128 0.0031765 0.0013794 
  
0.0006073 0.0025685 
55 0.0126175 0.0083194 0.0036179 
  
0.0015939 0.0060572 
65 0.0226729 0.0216977 0.0065306 
  
0.0028795 0.0142504 
75 0.0424430 0.0612442 0.0270464 
  
0.0119950 0.0333385 
Black women 
      
45 0.0034142 0.0020636 0.0008958 
  
0.0003944 0.0016158 
55 0.0069412 0.0054094 0.0023504 
  
0.0010352 0.0038130 
65 0.0132003 0.0141417 0.0061600 
  
0.0027158 0.0089843 
75 0.0282548 0.0402030 0.0176446 
  
0.0078044 0.0210944 
Hispanic men 
      
45 0.0026056 
 
0.0008874 
  
0.0003907 0.0018822 
55 0.0060763 
 
0.0023285 
  
0.0010255 0.0044408 
65 0.0124837 
 
0.0061026 
  
0.0026905 0.0104592 
75 0.0272090 
 
0.0174811 
  
0.0077317 0.0245326 
Hispanic women 
      
45 0.0014800 
 
0.0005763 
  
0.0002537 0.0011839 
55 0.0033205 
 
0.0015124 
  
0.0006659 0.0027946 
65 0.0074147 
 
0.0039665 
  
0.0017476 0.0065894 
75 0.0188635 
 
0.0113849 
  
0.0050268 0.0154967 
Figure S1. Prevalence estimates of PAD according to odds of PAD at a given 
demographic variables in NHANES and meta-analyzed odds ratio for age, sex, and 
race/ethnicity from six cohorts. 
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Figure S2. Observed vs. predicted risk of PAD by deciles of predicted risk (cross-validation by splitting NHANES according 
to 2-year cycles). 
 
1. 1999-2002 for development and 2003-
2004 for validation 
 
2. 1999-2000 and 2003-2004 for 
development and 2001-2002 for validation 
 
3. 2001-2004 for development and 1999-
2000 for validation 
 
 
  Statistics in a validation dataset 
  Chi2, p-value C-statistic 
Development Validation All deciles Bottom 5 deciles Top 5 deciles  
1999-2002 2003-2004 26.5, 0.0002 18.6, 0.0002 8.0, 0.14 0.736 
1999-2000 & 2003-2004 2001-2002 14.1, 0.11 6.5, 0.27 7.7, 0.17 0.786 
2001-2004 1999-2000 11.1, 0.28 6.7, 0.25 4.3, 0.54 0.801 
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Figure S3. Observed vs. predicted risk of PAD by deciles of predicted risk (NHANES 
1999-2004).  
 
 
 
 
Chi2 was 10.2 (p=0.35) in all deciles, 9.2 (p=0.08) in bottom 5 deciles, and 1.0 (p=0.95) in top 5 
deciles. C-statistic was 0.77. 
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